HELS — Hedgeye 130/30 Equity ETF

Is HELS overbought or oversold? Here is the current MarketMoodz read.

Overbought As of October 3, 2026

Hedgeye 130/30 Equity ETF (HELS) currently reads Overbought on the MarketMoodz overbought/oversold meter, as of October 3, 2026. The stock last closed at $23.86. The rating moved from Oversold to Overbought on October 1, 2026.

AI analysis

Hedgeye 130/30 Equity ETF (HELS) is an actively managed long-short equity vehicle whose performance hinges on manager stock selection and short positioning. With markets trading cautiously and flows favoring defensive assets, the ETF faces modest short-term downside risk as leveraged long exposure is constrained by risk-off sentiment; however, its long-short framework provides avenues to outperform in stock-picking environments.

Key factors

  • Active 130/30 strategy (130% long, 30% short) that can amplify returns when manager alpha is realized
  • Long-short approach can reduce net market exposure relative to pure long strategies in down markets if shorts perform
  • ETF wrapper provides intraday liquidity and transparency versus closed-end or mutual fund structures
  • Current market tone is risk-off with flows into defensive/safe-haven assets, limiting near-term upside for equity-oriented, active strategies
  • Limited recent filings and social sentiment data reduce visibility into positioning and short-side exposures

Risks

  • Amplified losses in sharp equity drawdowns due to 130/30 leverage and potential short squeeze dynamics
  • Short-side losses in broad market rallies or if stock-specific shorts are wrong
  • Concentration or factor exposure (e.g., tech, cyclical) that could underperform during rotations
  • Widening bid-ask spreads and lower liquidity during market stress could increase realized execution costs
  • Manager performance risk and potential tracking error versus benchmarks or peers

See today's live rating, score and targets

Members see the live hourly rating for HELS — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.